TDMS Study 05109-12 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TRIETHANOLAMINE
NTP Experiment-Test: 05109-12 Report: PEIRPT05
Study Type: CHRONIC Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 08/21/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 7 4 5 11
Natural Death 4 6 7 2
Survivors
Terminal Sacrifice 38 40 38 37
Natural Death 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (60) (60) (60) (60)
Intestine Small, Jejunum (60) (60) (60) (60)
Sarcoma, Metastatic, Skin 1 (2%)
Liver (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 3 (5%)
Hepatocellular Carcinoma 1 (2%) 4 (7%) 7 (12%) 5 (8%)
Hepatocellular Adenoma 13 (22%) 15 (25%) 12 (20%) 12 (20%)
Hepatocellular Adenoma, Multiple 11 (18%) 9 (15%) 13 (22%) 29 (48%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 3 (5%)
Ito Cell Tumor NOS, Multiple 1 (2%)
Mesentery (2) (5) (5) (5)
Histiocytic Sarcoma 1 (20%)
Fat, Sarcoma, Metastatic, Skin 1 (20%)
Pancreas (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (60) (60)
Capsule, Spindle Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Carcinoma 1 (2%)
Pituitary Gland (54) (59) (59) (59)
Adenoma 1 (2%)
Pars Distalis, Adenoma 4 (7%) 5 (8%) 4 (7%) 5 (8%)
Pars Intermedia, Adenoma 1 (2%) 2 (3%)
Thyroid Gland (60) (60) (60) (60)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 4 (7%) 2 (3%) 5 (8%) 5 (8%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (60) (59) (60)
Cystadenoma 5 (8%) 3 (5%) 2 (3%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 3 (5%) 2 (3%)
Teratoma NOS 1 (2%) 1 (2%)
Follicle, Cystadenoma 1 (2%)
Uterus (60) (60) (59) (60)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Lymph Node (4) (8) (6) (9)
Bronchial, Hemangiosarcoma, Metastatic,
Uncertain Primary Site 1 (25%)
Bronchial, Sarcoma, Metastatic, Skin 1 (17%)
Mediastinal, Sarcoma, Metastatic, Skin 1 (17%)
Page 3
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Teratoma NOS, Metastatic, Ovary 1 (13%)
Pancreatic, Histiocytic Sarcoma 1 (11%)
Lymph Node, Mandibular (57) (59) (59) (59)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Lymph Node, Mesenteric (54) (59) (56) (59)
Histiocytic Sarcoma 2 (3%)
Spleen (60) (60) (60) (60)
Hemangiosarcoma 3 (5%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%) 2 (3%)
Capsule, Sarcoma, Metastatic, Skin 1 (2%)
Thymus (55) (57) (58) (58)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Thymoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (58) (57) (60) (57)
Adenoma 1 (2%)
Hemangiosarcoma 1 (2%)
Skin (60) (60) (60) (60)
Inguinal, Subcutaneous Tissue, Osteosarcoma 1 (2%)
Neck, Subcutaneous Tissue, Sarcoma 1 (2%)
Pinna, Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Lumbar, Vertebra, Sarcoma 1 (2%)
Scapula, Osteosarcoma 1 (2%)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (2) (2)
Fibrosarcoma 1 (50%)
Diaphragm, Sarcoma, Metastatic, Skin 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (59)
Alveolar/Bronchiolar Adenoma 2 (3%) 5 (8%) 2 (3%) 5 (8%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (3%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (3%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Osteosarcoma, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Tissue NOS 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (2) (1)
Adenoma 1 (100%) 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (60) (60) (59) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 2 (3%) 3 (5%)
Leukemia Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 5 (8%) 3 (5%) 4 (7%)
Lymphoma Malignant Mixed 4 (7%) 4 (7%) 1 (2%) 7 (12%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 1 (2%) 2 (3%) 3 (5%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 46 44 52
Total Primary Neoplasms 60 73 68 95
Total Animals with Benign Neoplasms 36 36 33 46
Total Benign Neoplasms 46 46 45 65
Total Animals with Malignant Neoplasms 11 22 21 25
Total Malignant Neoplasms 14 25 22 29
Total Animals with Metastatic Neoplasms 1 3 3 3
Total Metastatic Neoplasm 2 10 8 3
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2 1 1
Total Uncertain Neoplasms 2 1 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 2 5 3 6
Natural Death 2 5 8 3
Survivors
Terminal Sacrifice 46 39 39 41
Natural Death 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (60) (60) (60) (60)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (60) (60) (60) (60)
Carcinoma 1 (2%)
Liver (60) (60) (60) (60)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 3 (5%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 2 (3%)
Hepatoblastoma 3 (5%)
Hepatocellular Carcinoma 10 (17%) 14 (23%) 8 (13%) 10 (17%)
Hepatocellular Carcinoma, Multiple 6 (10%) 8 (13%) 7 (12%) 5 (8%)
Hepatocellular Adenoma 10 (17%) 11 (18%) 13 (22%) 12 (20%)
Hepatocellular Adenoma, Multiple 18 (30%) 18 (30%) 17 (28%) 29 (48%)
Histiocytic Sarcoma 1 (2%)
Mesentery (3) (1)
Carcinoma, Metastatic, Pancreas 1 (33%)
Hepatoblastoma, Metastatic, Liver 1 (100%)
Pancreas (60) (60) (60) (60)
Carcinoma 1 (2%)
Stomach, Forestomach (60) (59) (60) (60)
Squamous Cell Carcinoma 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
Carcinoid Tumor NOS 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Capsule, Spindle Cell, Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 1 (2%) 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Hemangioma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Sarcoma 1 (2%)
Prostate (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Testes (60) (60) (60) (60)
Bilateral, Interstitial Cell, Adenoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (2) (2) (3) (1)
Lumbar, Histiocytic Sarcoma 1 (33%)
Mediastinal, Carcinoma, Metastatic, Pancreas 1 (50%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (50%)
Pancreatic, Hepatoblastoma, Metastatic, Liver 1 (100%)
Lymph Node, Mandibular (57) (57) (57) (57)
Lymph Node, Mesenteric (56) (57) (53) (55)
Page 8
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (53) (46) (57) (52)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Neck, Basal Cell Carcinoma 1 (2%)
Neck, Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Neck, Subcutaneous Tissue, Fat, Hemangioma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1)
Carcinoma, Metastatic, Pancreas 1 (100%)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 14 (23%) 11 (18%) 14 (23%) 8 (13%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 4 (7%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 5 (8%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (7%) 6 (10%) 3 (5%) 2 (3%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (5) (6) (1)
Adenoma 4 (100%) 5 (100%) 5 (83%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leukemia Lymphocytic 1 (2%)
Lymphoma Malignant Lymphocytic 3 (5%)
Lymphoma Malignant Mixed 4 (7%) 1 (2%) 5 (8%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05109-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIETHANOLAMINE Date: 05/20/95
Route: DERMAL,SOLUTION Time: 00:11:45
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 49 43 53
Total Primary Neoplasms 82 87 80 85
Total Animals with Benign Neoplasms 36 40 36 45
Total Benign Neoplasms 55 53 51 58
Total Animals with Malignant Neoplasms 20 30 25 24
Total Malignant Neoplasms 27 33 29 27
Total Animals with Metastatic Neoplasms 4 7 3 3
Total Metastatic Neoplasm 4 13 3 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------